LGALS3 and chronic lung disease: This work identifies alveolar macrophages as a significant source of Gal-3 that drives inflammation and the development of pulmonary fibrosis and confirms direct targeting of Gal-3 in the lung as an attractive novel therapy for both acute lung injury and chronic lung disease.